Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyradiotherapyRegional therapyVisceral SurgeryDiseaseBreast CancerColon CancerEsophageal CancerGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupAdenocarcinoma of the esophagogastric junction (AEG)CLDN18.2 positive and HER2 negativeEpCAM positiveHER2+Mismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)PD-L1+unfitICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C50.-C56C78.6MeSHBreast NeoplasmsCarcinoma, Ovarian EpithelialColorectal NeoplasmsEsophageal NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceARMANI: CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca (PID2933) or mFOLFOX-6 (OXAL85/CFOL400/FU2400), AEG/Gastric Ca (PID2939) -|- RAMU8/PACL80, AEG/Gastric Ca (PID327)ARTIST, Gastric CaCAPOX (CAPE1000/OXAL130), AEG/Gastric Ca, adj., A (PID689) -|- B (PID684) -|- C (PID689)CGOG1001 : TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID1258) -|- C2-6 (PID1301) -|- C7+ (PID1302)CheckMate-032: NIVO1/IPIL3, AEG/Gastric Ca (PID1492) -|- NIVO240 maint. (PID1493)CheckMate 649: mFOLFOX-6 (OXAL85/LCVR400/FU2400)/NIVO240, Esophageal Ca/AEG/Gastric Ca (PID1905) -|- NIVO240 maint.,(PID1910)CheckMate 649: NIVO360/CAPE1000/OXAL130, Esophageal Ca/AEG/Gastric Ca (PID1906) -|- NIVO360 Maint. (PID1911)CISP75/TEGA25, AEG/Gastric Ca (PID202) -|- TEGA25 maint. (PID1106)DANTE/IKF-s633: ATEZ840/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1-4.5-8 (PID2563) -|- C1-4.5-8 (PID2563) -|- ATEZ1200, C9-17 (PID2564)DOCE50/OXAL100/TEGA40, AEG/Gastric Ca, neoadj. (PID2038) -|- TEGA25, adj. (PID606)FU425/CFOL/20/Radiation, AEG/Gastric Ca, adj., A (PID697) -|- B (PID698) -|- C (PID697).GERCOR NEONIPIGA: NIVO240/IPIL1, AEG/Gastric Ca, perioperative, cycle 1-2 (PID2244) -|- NIVO480, cycle 3-11 (PID2245)GLOW: CAPOX(CAPE1000/OXAL130)/ZOLB800, AEG/Gastric Ca, C1 (PID2733) -|- C2-8 (PID2734) -|- Gastric Ca. (PID2735)KEYNOTE-059: PEMB200/CISP80/FU800, AEG/Gastric Ca (PID1451) -|- PEMB200/FU800 maint. (PID1507)KEYNOTE-585 (FLOT/PEMB)KEYNOTE-585: PEMB200/CISP80/CAPE1000, AEG/Gastric Ca, perioperative, C1-6 (PID2236) -|- PEMB200, C7-17 (PID2237).LEAP-015: mFOLFOX-6 (OXAL85/CFOL350/FU2400)/PEMB400/LENV8, AEG/Gastric Ca, C1-2 (PID2947) or CAPOX (CAPE1000/OXAL130)/PEMB400/LENV8, AEG/Gastric Ca, C1-2 (PID2948) -|- PEMB400/LENV20, C3-18 (PID2949)MATTERHORN: DURV1500/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1-4 (PID2952) -|- DURV1500, C5-14 (PID2953)mFOLFOX-6 (OXAL85/CFOL400/FU2400)/NIVO240/TRAS6, Esophagus Ca/AEG/Gastric Ca, C1 (PID2421) -|- C2+ (PID2422).PEMB200/TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID2101) -|- PEMB200/TRAS6/CISP80/FU800, C2+ (PID2102)PEMB200/TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID2093) -|- PEMB200/TRAS6/OXAL130/CAPE1000, C2+ (PID2094)RATIONALE-305: CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca (PID2933) -|- CAPOX (CAPE1000/OXAL130) - CAPE1000, Erh. (PID2934)RATIONALE-305: TISL200/CISP80/FU800, AEG/Gastric Ca (PID2937) -|- TISL200, maint. (PID2938) or TISL400, maint. (PID3063)RATIONALE-305: TISL200/OXAL130/CAPE1000, AEG/Gastric Ca (PID2935) -|- TISL200/CAPE1000, maint. (PID2936) or TISL400/CAPE1000, maint. (PID3062) -|- TISL200, maint. (PID2938) or TISL400, maint. (PID3063)SPOTLIGHTTEGA25, Gastric Ca, adj., C1 (PID872) -|- DOCE40/TEGA25, C2-7 (PID1394) -|- TEGA25, C8+ (PID1395)TRAS6/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1,5 (PID2034) -|- C2-4,6-8 (PID2035) -|- C9-17 (PID2036)TRAS8/CISP80/CAPE1000, AEG/Gastric Ca, C1 (PID221) -|- C2+ (PID220) -|- Maint. (PID222)TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID219) -|- C2+ (PID140) -|- maint. (PID222)Antineoplastic therapySubstanceAfliberceptAtezolizumabAvelumabCapecitabineCatumaxomabCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNaCl 0.9%NivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibSodium FolinateTegafurTislelizumabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCatumaxomabCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNaCl 0.9%NivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibSodium FolinateTegafurTislelizumabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCatumaxomabCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNaCl 0.9%NivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibSodium FolinateTegafurTislelizumabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineZolbetuximabSubstanceAfliberceptAtezolizumabAvelumabCapecitabineCatumaxomabCisplatinDocetaxelDurvalumabEpirubicinFluorouracilFolinic acidIpilimumabIrinotecanLenvatinibNaCl 0.9%NivolumabOxaliplatinPaclitaxelPembrolizumabRamucirumabRegorafenibSodium FolinateTegafurTislelizumabTrastuzumabTrastuzumab DeruxtecanTremelimumabTrifluridineZolbetuximabAnzahl Substanzen12345 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSodium ThiosulfateSubstanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSodium ThiosulfateAnzahl Substanzen12345678Protocol classificationTherapy classificationalternativecurrent standardspecial situationIntensityLow doseStandard doseTherapy indicationFirst lineRefractory diseaseSecond lineseveral possibleThird line Therapy phaseInductionintraoperativMaintenanceneoadjuvantneoadjuvant / adjuvantseveral possibleTherapy intentioncurativepalliativeRisksAbdominal PainAcute Kidney InjuryAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaBleedingCardiotoxicityCholinergic SyndromeColitisConstipationDiarrheaEdemaElectrolyte DisturbanceEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypoalbuminemiaHypokalemiaHyponatremiaHypophosphatemiaHypophysitisHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNephritisNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPancreatitisPneumoniaPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAjani JAAl-Batran SAl-Batran SEAndre TBang YBang YJCats ACenter for Esophageal and Gastric Cancer, Dana-Farber/Brigham and Women’s Cancer Center, Boston, ZAMEGA trialChao YCunningham DDi Lauro LFuchs CFuchs CSFukuoka SGhanipour LGong JGötze THall PSHeiss MMHironaka SHofheinz RDJanjigian YJanjigian YYKang JHKang YKato KKöhne CHLee JLee JLLorenzen SLorenzen S M. DankMacDonald JSMoehler MQiu MZQiu MZ Raimondi A Rha SYSakuramoto SShah MShah MAShitara KStein AThuss-Patience PWilke HYchou MYoshida KDiseaseAdeno-Ca des Magens oder des ösophagogastr. Überganges (Siewert II-III), cM0, MSI, EBV negativ, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, cT2 und höher oder cN+, M0Adeno-Ca des Magens oder des ösophagogastr. Überganges, HER2-positiv, cT2 und höher und/oder cN+, M0, ECOG 0-2Adeno-Ca des Magens oder des ösophagogastr. Überganges, mind. cT2 und/oder cN+, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IVA, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IV A, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II-IVA, ECOG 0-1Adenokarzinom des gastroösophagealen Übergangs oder des Magens, dMMR/MSI-H, cT2-4cN0/+cM0Adenokarzinom des Magens nach R0 Resektion und D2 Lymphknoten Dissektion, ECOG 0-1Adenokarzinom des Magens oder gastroösophagealen Übergangs nach R0 Resektion, Stadium Ib-IV, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, HER2+, ECOG 0-2Adenokarzinom ösophagogastraler Übergang und Magen, Her2-, CLDN18.2+, metastasiert oder inoperabel, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, lokal fortgeschritten, inoperabel, oder metastasiert, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, metastasiert, Erstlinie, ECOG 0-1AEG- oder Magenkarzinom, Adenokarzinom, Stadium II/III, ECOG 0-1AEG-Tumor und Magen-Ca (Adenokarzinom), metastasiert, Erstlinie, ECOG 0-2AEG/Magenkarzinom lokal fortschritten, inoperabel, mindestens 1 platinhaltige VortherapieChemonaive Patienten mit metastasiertem Magenkarzinomfortgeschrittenes Adenokarzinom des Magens/ösophagealen Übergangs, resezierbar, ECOG 0-1Fortgeschrittenes oder metastasiertes Adeno-Ca des Magens, des gastroösophagealen Übergangs oder des Ösophagus, HER2-negativ, ECOG 0-1fortgeschrittenes oder metastasiertes AEG, Magen- oder kolorektales Karzinom, refraktär oder intolerant, ECOG 0-1Fortgeschrittenes oder metastasiertes Karzinom des Ösophagus, gastroösophagealen Übergangs oder des Magens, Erstlinie, unfit Fortgeschrittenes oder rezidiviertes MagenkarzinomLokalisiertes oder lokal fortgeschrittenes Magen-Ca oder Karzinom des gastroösopagealen Übergangs Typ II/IIIMagenkarzinom, Stadium IB– IVA, perioperativ, ECOG 0-1Magenkarzinom, Stadium II-III, R0 nach D2-GastrektomieMagenkarzinom Stadium IIIA-IIIC nach R0-Resektion, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Progress nach platinbasierter Erstlinientherapie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4 Monaten nach Erstlinie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4/6 Monaten nach Erstchemo (adj. oder palliativ), ECOG 0-1Metastasiertes, nicht resektierbares Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-2Metastasiertes, oder nicht resektables Karzinom des gastroösophagealen Übergangs oder des Magens, Her2+, mind. 2 Vortherapien inkl. Trastuzumab-Vortherapie, ECOG 0-1metastasiertes Adeno-Ca des Magens und AEGmetastasiertes Adeno-Ca des Ösophagus, des gastralen Übergangs oder des Magens, ECOG 0-2Metastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, ECOG 0-1, ErstlinientherapieMetastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, ECOG 0-2, ErstlinientherapieMetastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, Her2-, metastasiert oder nicht resektabel, ECOG 0-1Metastasiertes Adenokarzinom des Magens oder des ösophagogastralen ÜbergangsMetastasiertes Adenokarzinom Karzinom des Ösophagus, ösophago-gastralen Übergangs oder Magens; Zweitlinie nach Kombination von Fluoropyrimidin mit CisplatinMetastasiertes AEG und Magenkarzinom, mindestens 2 Vorberhandlungen, PD-L1+Metastasiertes gastroösophageales Adeno-Ca.metastasiertes gastroösophageales Adeno-Ca.Metastasiertes gastroösophageales AdenokarzinomMetastasiertes Magenkarzinom, Erstlinie, ECOG 0-2Metastasiertes oder rezidiviertes Adenokarzinom des Magens ohne signifikante Peritonealkarzinose nach der Erstlinientherapie mit Fluoropyrimidin plus Platin, ECOG 0-2Neoadjuvante Chemotherapie bei resektablem Adenokarzinom des unteren Ösophagus, gastroösophagealen Übergangs oder Magensnicht-resezierbares, metastasiertes Magen-/AEG-Ca (Adeno-), Zweitlinie, ECOG 0-1nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, ERBB+, Erstlinie, ECOG 0-2nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, HER2+, Erstlinie, ECOG 0-2nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, Drittlinie, ECOG 0-1nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-1Patienten mit operiertem Karzinom des gastroösophagealen Übergangs oder des MagensPeritonealkarzinose, sekundärPeritonealkarzinose, sekundär, EpCAM positiv in malignen Zellen in Aszitesrezidiviertes oder metastasiertes Adenokarzinom des Magens / gastroösophagealen Übergangs, Erstlinie, ECOG 0-1unbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagusunbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagus, ECOG 0-1OriginAbteilung für Onkologie/Hämatologie, Kliniken Essen-Mitte, Deutschland, RAINBOW Study Group, RAINBOW StudieAIOArbeitsgemeinschaft Internistische OnkologieAsan Medical Center, University of Ulsan College of Medicine, Seoul, Prodigy trialausgedehnte MARGIT / AIO StudieCharite-University Medicine Berlin, Berlin, Germany, AIO-STO-0218 trialChiba Cancer Center, Chiba, Japan, WJOG 4007 TrialCleary JClinical Research Development Program of the Samsung Medical Center, Seoul, Korea.Cologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyDana-Farber Cancer Institute, Harvard Medical School, Boston, USA, REGARD StudieDepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, HoustonDepartment of Gastrointestinal Oncology, University Cancer Hospital and Institute, BeijingDepartment of Internal Medicine and Department of Surgery, Seoul, CLASSIC trialDepartment of Medicine, University of MainzDr. Roland Bugat, Institut Claudius Regaud, ToulouseFédération Nationale des Centres de Lutte Contre le Cancer, Fédération Francophone de Cancérologie DigestiveGifu University, Gifu, Japan, JACCRO GC-07 trialHematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany, AIO IntegaInstitute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, GermanyIstituto Nazionale Tumori IRCCS Milan, Milan, Italy, INFINITY study by GONOKeynote-059Kitasato University School of Medicine, Sagamihara, JapanKlinikum rechts der Isar, Klinik für Innere Medizin III, Technische Universität München, Munich, Germany, DANTE/IKF-s633Klinikum Rechts der Isar, Technische Universität München, München, Germany, RAMIRIS StudyM.D. Anderson Cancer Center, Houxton TXMemorial Sloan Kettering Cancer Center, A Study of the US Gastric Cancer ConsortiumMemorial Sloan Kettering CancerCenter, NY, Checkmate-032 StudieMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, Keynote-811Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA, CheckMate 649Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, MATTERHORN trialNational Cancer Center Hospital East, Chiba, Japan, TAGSNational Cancer Center Hospital East, Kashiwa, Japan, LEAP-015 studyNational Cancer Center Hospital East, Kashiwa, Japan, REGONIVO trial, EPOC1603National Cancer Center Hospital East, Kashiwa City, Japan, SPOTLIGHT trialNational Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan, DESTINY-Gastric01 trialNetherlands Cancer Institute, Amsterdam, Netherlands, CRITICS trialONO-4538-12, ATTRACTION-2PREVENT - FLOT9 trial of the AIO / CAOGI / ACORegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyResearch Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China, RATIONALE-305 trialRoyal Marsden Hospital, Surrey and London, UK, MAGIC trialSeoul National University College of MedicineSeoul National University College of Medicine, Seoul, Republic of Korea, KEYNOTE-585Seoul National University College of Medicine, TOGA StudieSeoul National University College of Medicine, ToGA studySorbonne University, Saint-Antoine Hospital, Paris, France, GERCOR NEONIPIGA studySt. Vincent´s Comprehensive Cancer Center, New YorkSungkyunkwan University School of Medicine, Seoul, Korea, The ARTIST trialTaipei Veterans General Hospital, Taipei, TaiwanUniversity of Leeds, United Kingdom, GO2 trialUniversity of Ulsan College of Medicine, Seoul, KoreaUniversitätsmedizin Mannheim, Universität Heidelberg, Mannheim, GermanyUppsala University, Uppsala, SwedenWeill Cornell Medical College, New York City, NY, USA, GLOW trialYale Cancer Center, Yale School of Medicine, KEYNOTE-059Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, KEYNOTE-859 trialProtocols in Revision 109 protocols foundAtezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - ATEZ1200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 9-17 (PID2564 V1.0)Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 1-4,5-8 (PID2563 V1.0)Avelumab 800 / Ramucirumab 8 / Paclitaxel 80, Adenocarcinoma Esophagogastric Junction and Stomach (PID2565 V1.0)Capecitabine 1000 / Cisplatin 60, Gastric Cancer, adjuvant (PID695 V1.3)Capecitabine 1000 / Cisplatin 80, adenocarcinoma esophagogastric junction and stomach (PID1417 V1.3)Capecitabine 1000 / Irinotecan 250, adenocarcinoma esophagogastric junction and stomach (PID1418 V1.2)Capecitabine 825 / Radiation, Gastric Cancer, adjuvant (PID2243 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Nivolumab 360, Esophagogastric Carcinoma, Esophagogastric junction and Stomach (PID1906 V1.2)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Pembrolizumab 400 / Lenvatinib 8, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1-2 (PID2948 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 600 - Zolbetuximab 600 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2735 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-8 (PID2734 V1.0)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Zolbetuximab 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2733 V1.0)CAPOX (Capecitabine 375 / Oxaliplatin 78), Esophagogastric Carcinoma, Esophagus, Esophagogastric junction and Stomach (PID1794 V1.2)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / TRAS 6, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-6 (PID1301 V1.2)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Trastuzumab 8, Adenocarcinoma Esophagogastric Junction and Stomach, C1 (PID1258 V1.2)CAPOX - Capecitabine 1000 / Oxaliplatin 130 - Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2934 V1.0)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach (PID2933 V1.0)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C (PID689 V1.3)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Gastric Cancer, adjuvant (PID696 V1.2)CAPOX / Radiation - Capecitabine 825 / Oxaliplatin 40 / Radiation, adenocarcinoma esophagogastric junction and stomach, adjuvant, Part B (PID684 V1.4)Catumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)Cisplatin 100 / Fluorouracil 800, adenocarcinoma esophagus, esophagogastric junction and stomach (PID136 V1.3)Cisplatin 75 / Tegafur 25, adenocarcinoma esophagogastric junction and stomach (PID202 V1.2)Docetaxel 40 / Fluorouracil 2000 / Cisplatin 40, adenocarcinoma esophagogastric junction and stomach (PID2171 V1.0)Docetaxel 40 / Tegafur 25, Gastric Cancer, adjuvant, cycle 2-7 (PID1394 V2.0)Docetaxel 50 / Oxaliplatin 100 / Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant (PID2038 V2.0)Docetaxel 60 / Oxaliplatin 100 / Capecitabine 500, adenocarcinoma esophagogastric junction and stomach (PID1230 V1.1)Docetaxel 60, Gastric Cancer (PID129 V1.1)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, adenocarcinoma esophagogastric junction and stomach (PID128 V1.4)Docetaxel 75, adenocarcinoma esophagus, esophagogastric junction, and stomach (PID134 V1.1)Durvalumab 1500 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Durvalumab 1500, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 5-14 (PID2953 V1.0)Durvalumab 1500 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-4 (PID2952 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)Epirubicin 50 / Cisplatin 60 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach (PID1776 V1.3)Epirubicin 50 / Cisplatin 60 / Fluorouracil 200, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant/adjuvant. (PID1228 V1.2)Epirubicin 50 / Oxaliplatin 130 / Capecitabine 625, adenocarcinoma esophagogastric junction and stomach (PID1775 V1.2)FLO - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID142 V1.2)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID67 V1.4)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach, perioperative (PID336 V1.4)Fluorouracil 400 / Folinic Acid 20 / Radiation, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, Part B (PID698 V1.2)Fluorouracil 425 / Folinic Acid 20, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C. (PID697 V1.2)FOLFIRI - Irinotecan 80 / Folinic Acid 500 / Fluorouracil 2000, adenocarcinoma esophagogastric junction and stomach (PID143 V1.2)FOLFIRI/RAMU - Ramucirumab 8 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, adenocarcinoma esophagogastric junction and stomach (PID1599 V1.0)HIPEC - Cisplatin 75, Adenocarcinoma Esophagogastric Junction and Stomach (PID2710 V1.1)Irinotecan 150, Gastric Cancer (PID1489 V1.0)Irinotecan 350, adenocarcinoma esophagogastric junction and stomach (PID139 V1.1)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach (PID1905 V1.1)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400), Adenocarcinoma Esophagogastric Junction and Stomach (PID2939 V1.0)mFOLFOX-6 - Nivolumab 240 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 - Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach, maintenance (PID1910 V1.1)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 2+ (PID2422 V1.0)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 6 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 1 (PID2421 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400) / Pembrolizumab 400 / Lenvatinib 8, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1-2 (PID2947 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab (800/600), Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2727 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 400 - Zolbetuximab 400 / Folinic Acid 400 / Fluorouracil 2400, Adenocarcinoma Esophagogastric Junction and Stomach, Maintenance (PID2892 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 400, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-12 (PID2891 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600 - Zolbetuximab 600 / Folinic Acid 400 / Fluorouracil 2400, Adenocarcinoma Esophagogastric Junction and Stomach, Maintenance (PID2803 V1.1)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600 - Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2732 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 600, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-4 (PID2731 V1.0)Modified FOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Zolbetuximab 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2890 V1.1)modified FOLFOX-6 - Aflibercept 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, carcinoma esophagus, esophagogastric junction and stomach (PID1915 V1.0)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID1493 V1.2)Nivolumab 1 / Ipilimumab 3, adenocarcinoma esophagogastric junction and stomach (PID1492 V1.2)Nivolumab 240 / Ipilimumab 1 - Nivolumab 480, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3-11 (PID2245 V1.0)Nivolumab 240 / Ipilimumab 1, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-2 (PID2244 V1.0)Nivolumab 240 / Regorafenib 80, Adenocarcinoma Esophagogastric junction, Gastric and Colorectal Carcinoma (PID580 V1.1)Nivolumab 240, adenocarcinoma esophagogastric junction and stomach (PID1381 V2.1)Nivolumab 360 / Capecitabine 1000 / Oxaliplatin 130 - Nivolumab 360 maintenance, Carcinoma Esophagus, Esophagogastric Junction and Stomach (PID1911 V1.0)Oxaliplatin 65 / Sodium Folinate 300 / Fluorouracil 2600, Gastric Cancer (PID2528 V1.0)Paclitaxel 80, Gastric Cancer (PID1488 V1.0)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000 - Pembrolizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17. (PID2237 V1.0)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-6. (PID2236 V1.0)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800 - Pembrolizumab 200 / Fluorouracil 800 maintenance, adenocarcinoma esophagogastric junction and stomach (PID1507 V1.1)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach (PID1451 V1.2)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Pembrolizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17 (PID2235 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1,4 (PID2232 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 2,5 (PID2233 V1.1)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3,6 (PID2234 V1.1)Pembrolizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach (PID2577 V1.0)Pembrolizumab 200 / Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2102 V1.1)Pembrolizumab 200 / Trastuzumab 6 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2094 V1.2)Pembrolizumab 200 / Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2101 V1.1)Pembrolizumab 200 / Trastuzumab 8 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2093 V1.2)Pembrolizumab 200, adenocarcinoma esophagogastric junction and stomach (PID1299 V1.1)Pembrolizumab 400 / Lenvatinib 20, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 3-18 (PID2949 V1.0)Ramucirumab 8 / Paclitaxel 80, adenocarcinoma esophagogastric junction and stomach (PID327 V1.2)Ramucirumab 8, adenocarcinoma esophagogastric junction and stomach (PID328 V1.1)Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID1106 V1.2)Tegafur 25, Gastric Cancer, adjuvant (PID606 V2.0)Tegafur 25, Gastric Cancer, adjuvant, cycle 1 (PID872 V2.0)Tegafur 25, Gastric Cancer, adjuvant, cycle 8+ (PID1395 V2.0)Tislelizumab 200 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2936 V1.1)Tislelizumab 200 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach (PID2937 V1.1)Tislelizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach (PID2935 V1.1)Tislelizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID2938 V1.1)Tislelizumab 400 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID3062 V1.0)Tislelizumab 400, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID3063 V1.0)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Trastuzumab 6, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 9-17 (PID2036 V1.1)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 2-4,6-8 (PID2035 V1.2)Trastuzumab 6 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 7+ (PID1302 V1.2)Trastuzumab 6 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID220 V1.5)Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID140 V1.3)Trastuzumab 6 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1.5 (PID2034 V1.1)Trastuzumab 6, maintenance, adenocarcinoma esophagogastric junction and stomach (PID222 V1.1)Trastuzumab 8 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID221 V1.5)Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID219 V1.3)Trastuzumab Deruxtecan 5,4, Adenocarcinoma Esophagogastric Junction and Stomach (PID1736 V1.2)Trastuzumab Deruxtecan 6.4, adenocarcinoma esophagogastric junction and stomach (PID2253 V1.0)Tremelimumab 300 / Durvalumab 1500, Adenocarcinoma Esophagogastric Junction and Stomach (PID2954 V1.0)Trifluridine 35, adenocarcinoma esophagogastric junction and stomach (PID62 V2.3)
